Shire Patent Suit Over Generic Intuniv Survives

Law360, New York (August 29, 2011, 7:38 PM EDT) -- A California federal judge on Monday denied Impax Laboratories Inc. and Watson Pharmaceuticals Inc.'s attempt to dismiss a patent infringement suit brought by Irish drugmaker Shire PLC over a generic version of its attention deficit hyperactivity disorder drug Intuniv.

When Shire moved to strike all of Impax and Watson's counterclaims and affirmative defenses in February for failure to state a claim, the defendants countered with a motion to dismiss the suit, saying their answers to Shire's complaint are pleaded in the same fashion as the complaint...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.